GlassScriptPhysician profile
Lori Ann Schwartz
NPI 1275273237
$1,078.98
in general payments reported to CMS, 2019-2025
18 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $260 · 2024: $566 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $399.79 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Exeltis, USA INC. | $123.98 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $100.83 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $87.17 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $60.99 | 2023-2024 | |
| Abbvie INC. | $42.26 | 2024 | |
| Merck Sharp & Dohme LLC | $40.70 | 2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $33.70 | 2024-2025 | Evenity, Prolia |
| Idorsia Pharmaceuticals US INC | $32.23 | 2023 | Quviviq |
| Bioventus LLC | $25.68 | 2025 | Exogen Ultrasound Bone Healing System |
| Dexcom, INC. | $25.26 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $18.69 | 2024 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $18.65 | 2025 | Sapien 3 Ultra Resilia |
| Glaxosmithkline, LLC. | $15.04 | 2024 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $13.87 | 2023 | Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.68 | 2025 | |
| Lilly USA, LLC | $13.26 | 2024 | Mounjaro |
| Exact Sciences Corporation | $13.20 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.